DNA Methylation-Based Classification of Kidney Neoplasms
- PMID: 40939817
- PMCID: PMC12517761
- DOI: 10.1016/j.modpat.2025.100884
DNA Methylation-Based Classification of Kidney Neoplasms
Abstract
Renal neoplasms are morphologically and molecularly heterogeneous, with their diagnosis often hindered by interobserver variability and overlapping microscopic features. A subset of cases is unclassifiable despite immunohistochemical, mutation, and cytogenetic-based diagnostic workup. Through examination of the genome-wide DNA methylation signatures of over 2000 renal neoplasms, we identified 23 coherent groups that correlate with known neoplasm types and identified novel clinically relevant subtypes of existing neoplasm types. We used machine learning models to develop and validate a classifier trained on DNA methylation profiles of 1284 samples. The classifier was tested on an external data set of 287 renal neoplasms with >90% concordance between expected neoplasm type and high-score DNA methylation-based classification. Discordance between the original histologic label and methylation class led to potential reclassification of some cases. This work demonstrates proof of principle for the feasibility of a DNA methylation classifier as a clinically useful tool to assist in the diagnosis of renal neoplasms.
Keywords: DNA methylation; epigenome; kidney cancer; machine learning; renal cell carcinoma; tumor classification.
Copyright © 2025 United States & Canadian Academy of Pathology. All rights reserved.
Conflict of interest statement
Declaration of interests
M.S. is a scientific advisor and shareholder of Heidelberg Epignostix and Halo Dx, and a scientific advisor of Arima Genomics, and InnoSIGN, and received research funding from Lilly USA, none related to this study. Other authors declare no competing interests.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
